Stock listing
NASDAQ:KROS Keros Therapeutics, Inc. Stock
Home listing (NASDAQ) of Keros Therapeutics, Inc.
Follow Keros Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KROS
$11.08 USD -0.92 (-7.7%)
Close on Nov 20, 2026
- Day range
- $11.04 – $11.59 USDNov 20, 2026
- Volume
- 208,691 sharesNov 20, 2026
- Market cap
- $219.7M USDAt the close on Nov 20, 2026 · price × 19.83M shares outstanding
- 52-week range
- $8.98 – $22.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.13M USDMedian day 180,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KROS · Home | $11.08 USD | -0.92 (-7.7%) | 208,691 | $11.13 | $11.59 | $11.04 | $12.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KROS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.08 | -0.92 | -7.7% | $11.13 | $11.59 | $11.04 | 208,691 | |
| $12.00 | +0.69 | +6.1% | $11.23 | $12.40 | $11.23 | 547,064 | |
| $11.31 | +1.28 | +12.8% | $10.02 | $11.76 | $10.02 | 423,103 | |
| $10.03 | -0.27 | -2.6% | $10.33 | $10.74 | $9.905 | 193,875 | |
| $10.30 | +0.22 | +2.2% | $10.06 | $10.55 | $9.55 | 167,040 | |
| $10.08 | +0.54 | +5.7% | $9.51 | $10.53 | $9.435 | 630,066 | |
| $9.54 | +0.21 | +2.3% | $9.37 | $9.725 | $9.23 | 221,662 | |
| $9.33 | +0.16 | +1.7% | $9.20 | $9.50 | $8.98 | 274,357 | |
| $9.17 | -0.19 | -2.0% | $9.50 | $9.87 | $9.10 | 144,125 | |
| $9.36 | -0.09 | -1.0% | $9.74 | $9.955 | $9.26 | 192,037 | |
| $9.45 | -1.38 | -12.7% | $10.84 | $10.98 | $9.37 | 238,369 | |
| $10.83 | 0.00 | 0.0% | $11.13 | $11.15 | $10.80 | 128,258 | |
| $10.83 | +0.07 | +0.7% | $10.78 | $11.11 | $10.78 | 105,963 | |
| $10.76 | -0.28 | -2.5% | $11.12 | $11.39 | $10.53 | 139,244 | |
| $11.04 | -0.32 | -2.8% | $11.36 | $11.49 | $10.98 | 120,157 | |
| $11.36 | -0.25 | -2.2% | $11.71 | $11.87 | $11.21 | 205,017 | |
| $11.61 | +0.185 | +1.6% | $11.34 | $11.79 | $11.20 | 183,223 | |
| $11.43 | +0.095 | +0.8% | $11.37 | $11.60 | $11.19 | 148,511 | |
| $11.33 | +0.05 | +0.4% | $11.30 | $11.51 | $11.20 | 112,409 | |
| $11.28 | -0.07 | -0.6% | $11.28 | $11.34 | $10.92 | 120,900 | |
| $11.35 | +0.17 | +1.5% | $11.15 | $11.44 | $11.15 | 115,500 | |
| $11.18 | -0.22 | -1.9% | $11.40 | $11.68 | $11.11 | 178,100 | |
| $11.40 | +0.34 | +3.1% | $11.04 | $11.67 | $11.04 | 153,400 | |
| $11.06 | +0.40 | +3.8% | $10.68 | $11.15 | $10.66 | 210,600 | |
| $10.66 | -0.44 | -4.0% | $11.11 | $11.13 | $10.63 | 169,600 | |
| $11.10 | +0.05 | +0.5% | $11.13 | $11.40 | $10.98 | 96,700 | |
| $11.05 | -0.18 | -1.6% | $11.07 | $11.30 | $10.92 | 159,100 | |
| $11.23 | -0.38 | -3.3% | $11.65 | $11.69 | $11.19 | 144,300 | |
| $11.61 | -0.34 | -2.8% | $11.77 | $12.08 | $11.58 | 223,700 | |
| $11.95 | +0.31 | +2.7% | $11.58 | $12.26 | $11.49 | 194,400 | |
| $11.64 | +0.43 | +3.8% | $11.13 | $11.76 | $10.99 | 245,700 | |
| $11.21 | +0.20 | +1.8% | $10.81 | $11.34 | $10.81 | 196,000 | |
| $11.01 | -0.51 | -4.4% | $11.56 | $11.63 | $10.95 | 185,300 | |
| $11.52 | +0.16 | +1.4% | $11.38 | $11.56 | $11.07 | 132,400 | |
| $11.36 | +0.10 | +0.9% | $11.38 | $11.44 | $11.01 | 231,500 | |
| $11.26 | -0.14 | -1.2% | $11.38 | $11.44 | $11.08 | 140,200 | |
| $11.40 | +0.21 | +1.9% | $11.25 | $11.58 | $11.16 | 131,200 | |
| $11.19 | -0.09 | -0.8% | $11.24 | $11.46 | $11.15 | 118,300 | |
| $11.28 | -0.34 | -2.9% | $11.33 | $11.41 | $10.93 | 208,600 | |
| $11.62 | +0.07 | +0.6% | $11.54 | $11.70 | $11.29 | 216,100 | |
| $11.55 | -0.08 | -0.7% | $11.60 | $11.60 | $10.97 | 284,400 | |
| $11.63 | -0.10 | -0.9% | $11.68 | $11.82 | $11.47 | 157,500 | |
| $11.73 | +0.25 | +2.2% | $11.54 | $12.05 | $11.43 | 189,800 | |
| $11.48 | +0.29 | +2.6% | $11.31 | $11.60 | $11.08 | 120,700 | |
| $11.19 | -0.17 | -1.5% | $11.32 | $11.40 | $11.10 | 302,500 | |
| $11.36 | +0.62 | +5.8% | $10.87 | $11.39 | $10.83 | 274,100 | |
| $10.74 | -0.43 | -3.8% | $11.23 | $11.23 | $10.70 | 273,600 | |
| $11.17 | -0.04 | -0.4% | $11.16 | $11.21 | $10.72 | 200,000 | |
| $11.21 | +0.13 | +1.2% | $11.10 | $11.34 | $10.98 | 342,200 | |
| $11.08 | -0.09 | -0.8% | $11.25 | $11.34 | $11.03 | 143,800 | |
| $11.17 | -0.14 | -1.2% | $11.16 | $11.20 | $11.00 | 128,800 | |
| $11.31 | +0.14 | +1.3% | $11.48 | $11.82 | $11.21 | 188,500 | |
| $11.17 | -0.15 | -1.3% | $11.16 | $11.31 | $10.98 | 73,000 | |
| $11.32 | +0.21 | +1.9% | $11.03 | $11.40 | $11.02 | 65,600 | |
| $11.11 | -0.12 | -1.1% | $11.27 | $11.32 | $10.92 | 148,700 | |
| $11.23 | +0.16 | +1.4% | $11.07 | $11.49 | $10.97 | 98,000 | |
| $11.07 | -0.01 | -0.1% | $11.02 | $11.13 | $10.83 | 96,200 | |
| $11.08 | +0.05 | +0.5% | $10.93 | $11.20 | $10.76 | 180,000 | |
| $11.03 | -0.20 | -1.8% | $11.15 | $11.16 | $10.58 | 328,300 | |
| $11.23 | +0.11 | +1.0% | $11.09 | $11.48 | $11.01 | 127,600 | |
| $11.12 | -0.56 | -4.8% | $11.66 | $11.66 | $11.08 | 113,600 | |
| $11.68 | +0.90 | +8.3% | $10.83 | $11.71 | $10.83 | 200,300 | |
| $10.78 | -0.25 | -2.3% | $11.12 | $11.12 | $10.72 | 217,100 | |
| $11.03 | +0.08 | +0.7% | $10.96 | $11.09 | $10.81 | 157,500 | |
| $10.95 | -0.15 | -1.4% | $11.09 | $11.10 | $10.55 | 203,100 |
- Ticker
- NASDAQ:KROS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 24 slides
Latest news
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
Nov 16, 2026
Closed $11.31 (+12.8%) on Nov 17, 2026
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $9.36 (-1.0%) on Nov 6, 2026
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Sep 29, 2026
Closed $11.19 (-0.8%) on Sep 29, 2026
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Sep 28, 2026
Closed $11.28 (-2.9%) on Sep 28, 2026
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Sep 8, 2026
Closed $11.31 (+1.3%) on Sep 9, 2026
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Aug 3, 2026
Closed $10.25 (+1.4%) on Aug 4, 2026
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Jul 30, 2026
Closed $10.07 (-1.5%) on Jul 31, 2026
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Jun 25, 2026
Closed $10.99 (+5.6%) on Jun 26, 2026
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 1, 2026
Closed $10.55 (-3.2%) on Jun 2, 2026
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
May 14, 2026
Closed $10.99 (-8.3%) on May 14, 2026
Keros Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 141 in all · newest Nov 16, 2026 · oldest 2020
- Decks
- 42 decks · latest Nov 5, 2026
Where Keros Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KROS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KROS | BOATS | United States | USD |
Valuation
EV/sales −0.6× against a median of 99.4×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$24.67M USD
- P/E
- Loss
- EV/sales
- −0.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- Not reported
- Operating margin
- −181.3%
- Net margin
- −152.7%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.16
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.6M | n/a | 403× | n/a | n/a | n/a | n/a | n/a |
| Aprilbio Co., Ltd. · KRX:397030 | US$221.1M | US$161.2M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Median of the others | US$218.1M | US$160.7M | 99.4× | 1.6× | −108.3% | 0.1× | 1.17 |
Forecasts
4 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.46 · 4 analysts
- Revenue, year to Dec 2026
- 40.82M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jasbir Seehra | President, Chief Executive Officer and Director |
| Annita Tanini | Corporate Controller and Vice President, Finance |
| Esther Cho | Chief Legal Officer |
| Lorena Lerner | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Jean-Jacques Bienaimé | Chairman |
| Alpna Seth | Director |
| Anne Prener | Director |
| Charles Newton | Director |
| Jasbir Seehra | President, Chief Executive Officer and Director |
| Julius Knowles | Director |
| Mary Ann Gray | Director |
| Nima Farzan | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −0.9% |
| Q2 2026 | Aug 3, 2026 · After close | +1.4% |
| Q1 2026 | Apr 30, 2026 | +3.5% |
| Q4 2025 | Mar 4, 2026 · After close | −15.0% |
| Q3 2025 | Nov 5, 2025 · After close | +3.3% |
| Q2 2025 | Aug 6, 2025 · After close | −7.3% |
| Q1 2025 | May 6, 2025 · After close | −0.4% |
| Q4 2024 | Feb 26, 2025 · Before open | +0.3% |
| Q3 2024 | Nov 6, 2024 · After close | +1.1% |
| Q2 2024 | Aug 7, 2024 · After close | −2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −0.8% |
| Q4 2023 | Feb 28, 2024 · After close | −0.8% |
| Q3 2023 | Nov 6, 2023 · Before open | −0.8% |
| Q2 2023 | Aug 7, 2023 · Before open | −1.7% |
| Q1 2023 | May 4, 2023 · After close | −3.1% |
| Q4 2022 | Mar 3, 2023 · After close | −12.0% |
| Q3 2022 | Nov 3, 2022 · Before open | +1.7% |
| Q2 2022 | Aug 4, 2022 · After close | +12.8% |
| Q1 2022 | May 5, 2022 · Before open | −7.2% |
| Q4 2021 | Mar 9, 2022 · After close | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 24 slides | Nov 5, 2026 |
| Investor Presentation (August 2026) | Investor deck | 24 slides | August 2026 |
| Investor Presentation (March 2026) | Investor deck | 24 slides | Mar 4, 2026 |
| Investor Presentation (January 2026) | Investor deck | 23 slides | Jan 9, 2026 |
| Investor Presentation (August 2025) | Investor deck | 34 slides | Aug 6, 2025 |
| Technical Presentation (May 2025) | Technical | 14 slides | May 29, 2025 |
| Proxy Contest (May 2025) | Proxy contest | 36 slides | May 21, 2025 |
| Proxy Contest (May 2025) | Proxy contest | 27 slides | May 19, 2025 |
| Corporate Update (March 2025) | Corporate update | 30 slides | Mar 31, 2025 |
| Investor Presentation (January 2025) | Investor deck | 38 slides | Jan 10, 2025 |
All 42 decks
IPO
Priced at US$16.00 a share on Apr 7, 2020.
- Price
- US$16.00 a share
- Shares offered
- 6,000,000 shares of common stock
- Offering size
- US$96 million
- Underwriters' option
- Up to 900,000 more shares
- Underwriters
- Jefferies, SVB Leerink, Piper Sandler, H.C. Wainwright & Co. · In the order on the cover
- Shares delivered
- On or about Apr 13, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 21, 2020 |
| Filed publicly | Mar 16, 2020 |
| Amended twice | Newest Apr 7, 2020 |
| Shares registered with an exchange | Apr 3, 2020 |
| Declared effective by the SEC | Apr 7, 2020 |
| Final prospectus, with the price | Apr 8, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 8, 2020 |
| EFFECT · Notice that a registration is effective | Apr 7, 2020 |
| S-1MEF · Registration of more shares for the same offering | Apr 7, 2020 |
| S-1/A · Registration statement, amended | Apr 7, 2020 |
| CERT · Exchange's certificate of listing | Apr 6, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 3, 2020 |
| CORRESP · Letter to the SEC | Apr 3, 2020 |
| CORRESP · Letter to the SEC | Apr 3, 2020 |
| S-1/A · Registration statement, amended | Apr 1, 2020 |
| CORRESP · Letter to the SEC | Mar 30, 2020 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 16, 2020 |
| S-1 · Registration statement | Mar 16, 2020 |
| UPLOAD · Letter from the SEC | Mar 9, 2020 |
| DRS/A · Draft registration statement, amended | Feb 27, 2020 |
| DRSLTR · Letter to the SEC with a draft | Feb 26, 2020 |
| UPLOAD · Letter from the SEC | Feb 13, 2020 |
| DRS · Draft registration statement | Jan 21, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 8, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 243.9M | 0 | 151.0K | 0 | 20.1M | 0 | 10.0M | 10.0M |
| Cost of revenue | 1.51M | 1.23M | 815.0K | 1.61M | 898.0K | 605.0K | 17.3M | 10.1M |
| Gross profit | 242.6M | 3.55M | 151.0K | -1.61M | 20.1M | -605.0K | -7.35M | -111.0K |
| Research and development | 129.6M | 173.6M | 135.3M | 87.3M | 55.1M | 33.9M | 17.4M | 10.1M |
| Selling, general and administrative | 46.8M | 40.8M | 34.8M | 27.5M | 21.3M | 12.8M | 3.18M | 1.58M |
| Operating income | 67.6M | -210.8M | -169.9M | -114.8M | -56.4M | -46.7M | -10.6M | -1.69M |
| Depreciation and amortization | 1.51M | 1.23M | 815.0K | 674.0K | 378.0K | 278.0K | 208.0K | 153.0K |
| EBITDA | 69.1M | -209.6M | -169.1M | -114.1M | -56.0M | -46.4M | -10.4M | -1.54M |
| Interest expense | 0 | 0 | 1.00K | 4.00K | 6.00K | 8.00K | 6.00K | |
| Income before tax | 91.9M | -187.1M | -153.0M | -104.7M | -56.7M | -45.5M | -12.3M | -1.08M |
| Income tax | 4.88M | 300.0K | 0 | 0 | 2.01M | -172.0K | 0 | 257.0K |
| Net income | 87.0M | -187.4M | -153.0M | -104.7M | -58.7M | -45.4M | -12.3M | -1.33M |
| Earnings per share, basic | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -6.08 | -0.15 |
| Earnings per share, diluted | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -6.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 287.4M | 559.9M | 331.1M | 279.0M | 230.0M | 265.9M | 7.02M | 23.3M |
| Receivables | 3.57M | 2.74M | 143.0K | 0 | 18.0M | 0 | 922.0K | |
| Inventory | 14.1M | -841.0K | 3.06M | 1.47M | 759.0K | |||
| Current assets | 315.4M | 588.9M | 347.3M | 285.8M | 251.4M | 267.7M | 8.93M | 25.5M |
| Property, plant and equipment | 4.30M | 4.24M | 4.13M | 2.02M | 1.33M | 724.0K | 708.0K | 1.38M |
| Total assets | 338.0M | 615.9M | 370.0M | 306.8M | 255.3M | 269.4M | 11.0M | 27.4M |
| Accounts payable | 1.97M | 4.60M | 5.45M | 3.34M | 3.65M | 2.15M | 2.09M | 501.0K |
| Current liabilities | 20.4M | 27.4M | 24.4M | 16.5M | 11.8M | 7.18M | 4.49M | 11.5M |
| Long-term debt | 4.96M | 2.39M | ||||||
| Total debt | 16.9M | 18.9M | 14.4M | 13.3M | 1.09M | 899.0K | 5.33M | 2.56M |
| Total liabilities | 34.9M | 44.3M | 37.8M | 29.4M | 12.1M | 7.72M | 10.5M | 14.7M |
| Shareholders' equity | 303.1M | 571.6M | 332.2M | 277.4M | 243.2M | 261.7M | -19.4M | 12.8M |
| Shares outstanding | 19.5M | 40.6M | 31.8M | 27.5M | 24.0M | 23.2M | 2.43M | 8.88M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 107.5M | -160.9M | -124.5M | -70.1M | -62.1M | -36.9M | -16.0M | 7.04M |
| Capital spending | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M | -294.0K | -271.0K | -217.0K |
| Free cash flow | 106.0M | -162.8M | -127.0M | -71.3M | -63.2M | -37.2M | -16.3M | 6.83M |
| Cash from investing | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M | -294.0K | -271.0K | -217.0K |
| Cash from financing | -378.5M | 391.8M | 179.0M | 120.3M | 28.6M | 296.0M | 14.0K | 11.5M |
| Share buybacks | -375.0M | 0 | 120.3M | 28.6M | 299.0M | 14.0K | 11.5M | |
| Change in cash | -272.5M | 229.0M | 52.0M | 49.0M | -34.6M | 258.9M | -16.3M | 18.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 17, 2026 | Other filings | SEC |
| DEL AM | Sep 11, 2026 | Other filings | SEC |
| S-3 · Registration statement | Sep 10, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 22, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 4/A · Change in ownership, amended | Mar 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| SC TO-I/A | Nov 20, 2025 | Acquisition or disposal | SEC |
| SC TO-I/A | Nov 19, 2025 | Acquisition or disposal | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 22, 2025 | Big-stake notice | SEC |
| SC TO-I | Oct 20, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 15, 2025 | Big-stake notice | SEC |
| SC TO-C | Oct 15, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 15, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 21, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 6, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| 8-K · Current report | Jul 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 11, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Current report | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | May 27, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | May 8, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 18, 2025 | Material contract | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 11, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 11, 2025 | Big-stake notice | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Apr 10, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Dec 12, 2024 | Current report | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 8-K · Current report | Dec 3, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 8-K · Current report | Nov 6, 2024 | Current report | SEC |
| 8-K · Current report | Oct 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 8-K · Current report | Aug 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 7, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jun 17, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
This page holds 200 of 543 filings. Open Filings
Cap table
Built by 6ix from Keros Therapeutics, Inc.’s releases
- Common shares
- 19,827,188
- Fully diluted
- 19,827,188
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 19,827,188 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 19,827,188 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Since at least Apr 7, 2020 |
| Mary Ann Gray Other companies: Compass Therapeutics, Inc. (President, Gray Strategic Advisors, LLC · Since at least Apr 26, 2022); BioAtla, Inc. (Director · Since at least Dec 15, 2020); RAPT Therapeutics Inc (Director · Since at least Dec 4, 2019); Palisade Bio, Inc. (Director · Jul 19, 2019 – Nov 21, 2023 · Past); Sarepta Therapeutics, Inc. (Director · Dec 10, 2018 – Mar 7, 2022 · Past); SELLAS Life Sciences Group, Inc. (Director · Apr 25, 2016 – Oct 10, 2017 · Past); Juniper Pharmaceuticals Inc (Director · Mar 23, 2016 – Aug 14, 2018 · Past); Tetralogic Pharmaceuticals Corp (Director · Nov 5, 2014 – Jan 28, 2015 · Past); Senomyx Inc (Director · Sep 27, 2010 – Nov 2, 2018 · Past); GTC Biotherapeutics Inc (Director · Dec 6, 2007 – Jun 24, 2008 · Past); ACADIA Pharmaceuticals Inc. (Director · Jun 13, 2006 – Jun 7, 2016 · Past); Dyax Corp (Director · May 17, 2006 – Jan 14, 2016 · Past) | Director · Since at least Dec 17, 2020 |
| Jean-Jacques Bienaimé Other companies: Ascendis Pharma A/S (Board Member · Since at least Mar 23, 2026); Immunome, Inc. (Director · Since at least Nov 7, 2023); Incyte Corporation (Director · Since at least Jan 20, 2015); Immunic, Inc. (Director · Apr 16, 2014 – Sep 24, 2018 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 16, 2014 · Past); InterMune Inc (Director · Mar 26, 2012 – Sep 29, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Feb 7, 2012 · Past); BioMarin Pharmaceutical Inc. (Director · Jan 3, 2006 – May 20, 2024 · Past) | Chairman · Since at least Jun 1, 2024 |
| Ran Nussbaum Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Oct 21, 2022 · Past); ArQule Inc (Director · Nov 8, 2017 – Jan 16, 2020 · Past); VBI Vaccines Inc. (Director · Oct 30, 2017 – Oct 30, 2017 · Past); Kite Pharma Inc (Director · Jun 19, 2014 – Oct 3, 2017 · Past) | Director · Since at least Apr 7, 2020 |
| Charles Newton Other companies: Novavax, Inc. (Director · Since at least Apr 25, 2025); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); Lyell Immunopharma, Inc. (Chief Financial Officer · Since at least Jun 16, 2021); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past) | Director · Since at least Feb 26, 2026 |
| Tomer Kariv Other companies: 89bio Inc (Director · Nov 8, 2019 – Nov 11, 2019 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Dec 19, 2019 · Past); VBI Vaccines Inc. (Director · Jan 23, 2018 – Jan 31, 2019 · Past); Arno Therapeutics Inc (Director · Jan 12, 2016 – Sep 8, 2016 · Past) | Director · Since at least Apr 7, 2020 |
| Anne Prener Other companies: Damora Therapeutics, Inc. (Director · Since at least Jan 8, 2021); Kaleido Biosciences, Inc. (Director · Apr 1, 2020 – Jun 30, 2021 · Past); Rubius Therapeutics Inc (Director · Dec 17, 2019 – May 12, 2022 · Past) | Director · Since at least Jun 25, 2026 |
| Alpna Seth Other companies: Bio-Techne Corp (Director · Since at least Oct 26, 2017); Seagen Inc (Director · Mar 15, 2018 – Dec 14, 2023 · Past) | Director · Since at least May 1, 2023 |
| Nima Farzan Other companies: Latigo Biotherapeutics, Inc. (President and CEO, Director · Since at least Aug 6, 2026); Kinnate Biopharma Inc (CHIEF EXECUTIVE OFFICER, Director · Dec 2, 2020 – Apr 3, 2024 · Past) | Director · Since at least Apr 7, 2020 |
| Yung H Chyung Other companies: Tourmaline Bio Inc. (Chief Medical Officer · Oct 19, 2023 – Oct 19, 2023 · Past); Scholar Rock Holding Corporation (Chief Medical Officer · May 23, 2018 – Feb 14, 2022 · Past) | Chief Medical Officer · Nov 1, 2024 – Feb 18, 2025 · Past |
All 21 people
| Person | Seat |
|---|---|
| Alon Lazarus Other companies: Werewolf Therapeutics, Inc. (Director · Since at least Dec 23, 2020) | Director · Apr 7, 2020 – Apr 13, 2020 · Past |
| Christopher Rovaldi Other companies: Acceleron Pharma Inc (SVP, Program Mgmt and Ops · Apr 28, 2017 – Apr 3, 2018 · Past) | Chief Operating Officer · Feb 1, 2022 – Feb 18, 2025 · Past |
| Keith Regnante Other companies: Wave Life Sciences Ltd. (Chief Financial Officer · Aug 16, 2016 – Mar 7, 2019 · Past) | CHIEF FINANCIAL OFFICER · Since at least Apr 7, 2020 |
| Simon Peter Cooper Other companies: Morphic Holding Inc (CMO · Mar 18, 2024 – Aug 16, 2024 · Past) | CHIEF MEDICAL OFFICER · Aug 2, 2021 – Feb 13, 2024 · Past |
| Annita Tanini | Corporate Controller and Vice President, Finance · Since at least Aug 4, 2026 |
| Claudia Ordonez | Chief Medical Officer · Apr 7, 2020 – Jun 11, 2021 · Past |
| Esther Cho | Chief Legal Officer · Since at least Aug 6, 2025 |
| Jasbir Seehra | President, Chief Executive Officer and Director · Since at least Apr 7, 2020 |
| Jennifer Lachey | Chief Scientific Officer · Apr 7, 2020 – Jul 15, 2022 · Past |
| Julius Knowles | Director · Since at least Apr 7, 2020 |
| Lorena Lerner | Chief Scientific Officer · Since at least Aug 6, 2025 |
Log in to ask 6ix AI your own questions about Keros Therapeutics, Inc.